Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sofosbuvir + velpatasvir + GS-9857 versus sofosbuvir + velpatasvir in DAA-experienced chronic hepatitis C without prior NS5A inhibitor exposure
2015-003167-10Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic hepatitis C (CHC) comparing Sofosbuvir + velpatasvir + GS-9857 for 12 weeks with Sofosbuvir + velpatasvir for 12 weeks (2 arms). Primary endpoint: SVR12. Started Nov 2015; status: completed.
02
Drugs
sofosbuvirvelpatasvirvoxilaprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2015-003167-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003167-10.